Abstract Hematologic oncologists now have at their disposal (or a referral away) a myriad of new options to get from point A (a patient with relapsed or poor-risk disease) to point B (potential tumor eradication and long-term disease-free survival). In this perspective piece, we discuss the putative mechanisms of action and the relative strengths and weaknesses of currently available cellular therapy approaches. Notably, while many of these approaches have been published in high impact journals, with the exception of allogeneic stem cell transplantation and of checkpoint inhibitors (PD1/PDL1 or CTLA4 blockade), the published clinical trials have mostly been early phase, uncontrolled studies. Therefore, many of the new cellular therapy approaches have yet to demonstrate incontrovertible evidence of enhanced overall survival compared with controls. Nonetheless, the science behind these is sure to advance our understanding of cancer immunology and ultimately to bring us closer to our goal of curing cancer.
Introduction
The immune system plays an important role in control of cancer and in some situations adoptive transfer of immune cells can mediate tumor regression. In this review, we will highlight the evidence for this effect and endeavor to explain the relative roles as well as the potential advantages and disadvantages of various forms of cellular therapy. This review will not include cancer vaccines, which are immunotherapies that are designed solely to reduce the risk of relapse by enhancing pre-existing immunity. Similarly, antibodies including antibody-drug conjugates will not be reviewed here.
Broadly speaking, adoptive cellular therapy can be divided into two categories: Allogeneic hematopoietic cell transplantation (HCT), cytokines that increase effector cell numbers, inhibitory receptor blockade (so-called checkpoint blockade), and adoptive transfer of natural killer (NK) cells or tumorinfiltrating lymphocytes (TILs) belong to the class of approaches that do not rely on a priori knowledge of target molecules. In contrast, chimeric antigen receptor-redirected T cells (CART cells), bi-specific T cell-engaging antibodies (BiTEs), and T cell receptor (TCR) transgenic T cells require a priori knowledge and design that take into account possible target antigens.
While cellular immunotherapy may or may not be directed against a single molecule or antigen, in terms of effector functions, it conceptually represents an opposite approach to that of Bprecision medicine^with small molecule pathway inhibitors. Small molecule drugs achieve a favorable therapeutic index through inhibition of a single pathway that is critical for survival of cancer cells and not of normal cells. Furthermore, small molecule inhibitors are typically cytostatic and their function may be abrogated by a single mutation in a binding site or by upregulation of compensatory signalling pathways [1] [2] [3] . In contrast, T cells and other immune effector cells exert a variety of killing mechanisms simultaneously through production of granzymes, perforin, FasL, TRAIL, and myriad cytokines, and theoretically it would be difficult for a cancer cell to escape from all of these killing mechanisms at the same time [4, 5] . Notably, escape from potent immunotherapies has recently been described through loss of the target antigen, highlighting the fact that the most efficient way for a cancer cell to escape immunotherapy is to avoid detection [6•, 7] . Data on the most important T cell function(s) mediating cancer cell death after adoptive cellular therapy are lacking.
At present, cellular immunotherapy is reserved for patients who fail traditional chemotherapy. One of the strongest adverse prognostic markers for response to cytotoxic chemotherapy is mutation or deletion of the tumor suppressor gene p53. Several clinical observations suggest that p53-mediated apoptosis is not required for susceptibility to immune effector cell-based killing; for example, in chronic lymphocytic leukemia (CLL), the presence of a p53 mutation or 17p deletion does not impact the response rates to the anti-CD52 monoclonal antibody alemtuzumab or to the BTK inhibitor ibrutinib [8] [9] [10] . These observations raise the tantalizing possibility that traditional biological adverse prognostic factors will become less important when viewed through an immunotherapeutic prism, though intriguingly, a link between p53 and cancer immunosurveillance has been posited [11, 12•] .
An additional advantage of adoptive cellular therapy is that due to properties such as expansion, persistence, and memory formation patients need only receive a single dose of cells, thus abrogating the requirement for serial administration of drugs with potential logistical and financial implications [12•, 13•, 14•, 15•, 16•, 17]. Notably however, BITE molecules require continuous infusion over several cycles [18•] . It is unknown how long adoptively transferred T cells need to persist, but evidence from longterm relapses of CML patients successfully treated with alloHCT indicate that relapses can occur 10+ years later, though it is unknown whether this due to failure of immunosurveillance which would otherwise keep at bay rare malignant Bstem cells,^and whether more effective initial immune attack would be able to eradicate these rare stem cells [19] .
The predominant immune effector cell types used in adoptive cellular therapy include T cells (including CIK cells) [20] and NK cells [21] [22] [23] [24] . These cell types were chosen on the basis of known or purported effector functions in the endogenous immune system. There are overlapping functions between T cells and NK cells. Notably, in a healthy immune system, all these cell types function together and therefore a reductionist approach that relies upon transfer of selected cell populations or cell subtypes may fail to engender an optimal immune response.
Ultimately, the best way to study the different approaches to cellular therapy is to examine the mechanisms of failure of each of those in published studies, in order to best inform how we might improve in the future.
A. No a Priori Knowledge of Targets

Allogeneic Hematopoietic Cell Transplantation (HCT)
The antitumor effect of HCT is mediated predominantly by T cells, as maneuvers to deplete T cells in the stem cell graft clearly lead to an increased relapse rate [25] . There is also evidence for a role of NK cells, since some groups have shown that mismatches in NK receptor and ligand between donor and recipient can lead to a decrease in the relapse rate [26, 27] . The targets of the so-called graft-versus-leukemia effect are generally unknown, with few exceptions, and donor T cells are generally thought to be responding to polymorphic peptides presented by HLA molecules that are shared by donor and host (so-called minor histocompatibility antigens) [28] . Nonetheless, alloreactivity alone engenders a relatively weak antitumor response, perhaps because few of the transferred T cells have specificity for the relevant antigens [28, 29] . In situations where the transferred T cells can recognize the HLA molecules themselves (e.g., haploidentical transplantation), the patient is heavily immunosuppressed or T cell depletion must be performed in order to limit the development of prohibitively high rates of GVHD [30] . Furthermore, alloreactivity by itself is clearly insufficient to mediate an efficient antitumor effect because the dose intensity of the conditioning regimen is still important; recent data published in abstract form from a multicentre clinical trial comparing MAC to RIC showed better disease control in the MAC arm [31] . Finally, recent data show that patients transplanted in morphologic complete remission but with minimal residual disease had an inferior disease control, suggesting that the GVT is quite weak indeed [32] . Thus, although alloHCT is the prime example and most commonly performed example of adoptive immunotherapy for the treatment of cancer, it is complex, expensive, and despite all these, as currently performed it mediates a relatively minor antitumor effect.
Cytokines to Increase Effector Cell Numbers
Given the central role of T cells and NK cells in antitumor immunity, efforts have been made to administer cytokines in order to increase the number or activation status of the cells. The first cytokine to be so used was IL-2 [33] . Exogenous administration of IL-2 leads to an increase in T cells and NK cells and has been used in the treatment of melanoma and some other malignancies, generally with response rates of 5-15 % [34] . Notably, IL-2 also increases the numbers of regulatory T cells and has been used for the treatment of conditions associated with immune over-activation such as chronic graftversus-host disease (GVHD) [35] . While IL-2 thus maintains T cell tolerance, the other gamma chain cytokine IL-7 supports the development and homeostasis of naïve and memory T cells, and IL-15 supports NK cells and memory CD8 T cells in particular [36] . Administration of recombinant human IL-7 to patients leads to a preferential expansion of naïve CD4 and CD8 T cells along with an increased TCR diversity yet without significant antitumor effect [37, 38] . Administration of recombinant human IL-15 leads to expansion of NK cells, gamma-delta T cells, and memory CD8 T cells in patients with cancer; however, preliminary reports of antitumor efficacy were disappointing [39] . Both IL-7 and IL-15 are currently in clinical trials for patients with cancer.
NK Cells
NK cells are innate lymphocytes that can recognize cells transformed by viruses or malignancies. Recognition is based on a complex set of rules that include absence of stimulation through inhibitory receptors (missing self) as well as activation via a restricted set of activating receptors eg NKG2D, natural cytotoxicity receptors (NCR) [40] . NK cells can be shown to mediate potent cytotoxicity in vitro and do not mediate GVHD even after transfer into allogeneic recipients [41] . Adoptive transfer of NK cells has been investigated in several settings. Transfer of ex vivo expanded autologous NK cells into patients with advanced malignancies is well tolerated but antitumor responses have been minimal [42] . In the haploidentical setting, a series of clinical trials in patients with active AML has demonstrated that chemotherapy conditioning, high endogenous IL-15 levels, and depletion of endogenous regulatory T cells induce the best conditions for NK cell persistence and expansion, with some leukemia patients achieving a complete response and a median disease-free survival of 6 months in a subgroup of the patients [22] . Human cytokine-induced memory-like NK cells that exhibit enhanced effector functions are produced by brief pre-activation with IL-12, IL-15, and IL-18 followed by adoptive transfer, and a clinical trial is in progress in patients with AML [43] .
Tumor Infiltrating Lymphocytes
This concept was advanced by the NCI group. The principle is that T cells with tumor specificity are enriched within the tumor microenvironment (e.g., melanoma deposits, or marrow in some hematologic malignancies). There is a complex manufacturing protocol that over several weeks results in extensive expansion of terminally differentiated cells for infusion. Experience obtained from these studies was very important in advancing the field of adoptive cell therapy, demonstrating the importance of lymphodepleting chemotherapy and highlighting that autoimmune complications such as vitiligo or uveitis can occur from on-target specificity of the transferred cells, correlating with an antitumor response [44] [45] [46] . This modality has been particularly successful in melanoma, resulting in a complete response rate of approximately 25 %, likely due to the fact that melanoma carries a relatively high rate of mutations that can be recognized by T cell receptors. Marrow-infiltrating lymphocytes (MILs that were expanded ex vivo with anti-CD3/CD28 beads and IL-2) from patients with myeloma have been infused into 25 patients with some evidence that an anti-myeloma immune response correlated with responses post-high dose chemotherapy [47] .
Recently, T cells with tumor specificity have been shown to circulate in the peripheral blood and to express the activation/ exhaustion marker PD-1 [48] . Advances in TIL approaches have finessed the concept of antigen specificity and require a priori knowledge of tumor targets but have not yet been used in hematologic malignancies. These approaches require whole exome sequencing for individual mutations, followed by gene transfer of minigenes that encode the mutations into autologous antigen presenting cells (APC). Only those T cell clones that show an immunological response to the APC are then expanded ex vivo. This approach has been shown to work in a very limited number of patients to date and is extremely resource and time intensive [49•] .
Checkpoint Blockade
The use of inhibitory receptor blocking antibodies has been recently reviewed extensively [50] . A recent meta-analysis of randomized clinical trials showed an overall survival advantage to receiving checkpoint inhibitors with a hazard ratio of approximately 0.75 [51] . Despite the marked enthusiasm for these agents, it is notable that the minority of patients with solid tumors respond to single agent therapy. In Hodgkin lymphoma, due to overexpression of PD-L1, there appears to be a high response rate although follow up to date is quite short [52] . The challenges in this field include predicting which patients will respond, defining the optimal combination with other checkpoint inhibitors or with other agents such as chemotherapy or radiation, how to further enhance response rates, and dealing with the emergence of previously unseen autoimmune complications that arise from removing the brakes in a potentially indiscriminate manner on T cells without known specificity [53•, 54, 55] .
B. A Prior Knowledge of Targets Is Required
Viral-Specific T Cells
Malignancies that arise from viral reactivation can be treated with viral antigen-specific adoptive T cell therapy. In this instance, patient or donor T cells are expanded ex vivo in the presence of antigen presenting cells pulsed with viral peptides. Culture lasts several weeks, as the precursor frequency of viral-specific T cells is quite low. Furthermore, this product cannot easily be made from naïve donors who have not previously been exposed to the target virus. An advantage is that by definition, these cells have restricted T cell receptor specificity to the virus and hence are not capable of causing GVHD. Viral-specific T cells have been produced against EBV and used in the setting of patients with Hodgkin or non-Hodgkin EBV-associated lymphoma, leading to a complete response rates of approximately 50 % in the settings of active disease [56] . However, the major disadvantage here is that relatively few viruses cause cancers that express viral antigens. Viral-specific T cells have also been used in the setting of allogeneic CAR T cell therapy in order to limit the possibility of GVHD [57] .
Chimeric Antigen Receptor Redirected T Cells (CAR T Cells)
If a tumor cell surface antigen is known, single chain variable fragments (the antigen recognition domain) of an antibody can be genetically encoded into a novel polypeptide that also incorporates signalling and costimulatory domain, typically derived from molecules that are normally found in T cells. This polypeptide is a chimeric antigen receptor that upon binding its ligand transduces a T cell activation signal that leads to proliferation, cytokine production, and degranulation of effector molecules. Results using CAR T cells against CD19 are most advanced and have been reviewed elsewhere in this edition. In brief, however, the last few years have illustrated the potential power of CAR T cells and their potential drawbacks. Anti-CD19 CAR T cells can lead to complete response rates of up to 90 % in heavily pretreated patients with acute lymphoblastic leukemia (ALL), in per-protocol analyses [13•, 15•, 16•]. These high response rates are tempered by the requirement for individual product manufacturing for each patient, the high costs of gene transfer technology (usually viral transduction with retrovirus or lentivirus), and emerging problems such as limited persistence in some patients and the observation of antigen-loss relapses [6•, 13•, 15•, 16•]. Preliminary results indicate that molecules other than CD19 can also be effectively targeted [58, 59] . Future developments in the field will include suicide-gene approaches, combinatorial logic-gated designs, and multi-antigen specificity.
T Cell Receptor Transgenic T Cells
Most tumor-associated antigens (TAA) are intracellular molecules and must be targeted using TCR that are specific for TAA peptides that are presented in the context of the MHC class I or II groove on APC and tumor cells. There was evidence of an antitumor response in 2 of 11 AML patients receiving healthy donor-derived T cell clones specific for the tumor-associated antigen WT1 post allogeneic HCT [60] .
However, most TCR with specificity for self antigens have relatively low affinity (unlike T cells with specificity for viral antigens) [61, 62] . Therefore, high affinity TCR may be engineered into otherwise polyclonal T cells. This can be done either by cloning Bnatural^antigen-specific TCR from donors who happen to have high affinity TCR, or by Baffinity enhancement^of the TCR by mutating residues in the antigen recognition domain [63] [64] [65] . While this approach augments antitumor responses, affinity enhancement can lead to unanticipated novel cross-reactivity with self antigens that leads to potentially catastrophic consequences [66, 67] . Additional potential issues include mis-pairing between the endogenous and the introduced TCR alpha or beta chains, also leading to novel and unanticipated specificity [68] . Nonetheless, adoptive transfer of T cells with specificity for MAGEA3, NY-ESO1, CEA, and MART1 have been reported in clinical trials [67, [69] [70] [71] [72] . Of 20 patients with multiple myeloma (MM) treated with NYESO1-LAGE1-specific T cells, 16 achieved encouraging clinical responses [72] . Of 17 patients with melanoma treated with MART1-specific TCR transgenic T cells, 2 achieved partial responses along with T cell persistence [71] . The reasons for failure have not been comprehensively reported but may include HLA molecule downregulation, lack of presentation of the intracellular antigens, antigen loss or mutation, and failure of T cell persistence.
T Cell Engaging Antibodies
An alternative way to redirect T cells to a selected cell-surface target antigen is by infusing bi-specific T cell engaging antibodies that are specific for the CD3 molecule on the T cell and an antigen of choice such as CD19 on the target cells. Similar constructs have been that engage CD16 on NK cells [23] . The leading example of bi-specific T engaging antibodies is blinatumomab, a compound that has recently gained FDA approval for the treatment of Philadelphia chromosomenegative B-ALL. Approximately 40 % of patients treated in active disease achieve a complete response, and 80 % of patients treated in a minimal residual disease state achieve a MRD negative setting [18•, 73] . Administration must be via continuous intravenous infusion for 4 weeks on and 2 weeks off and continues for up to 5 cycles-although whether a longer duration of administration would enhance diseasefree survival without additional therapy is at present unknown. This point would be best informed by long-term clinical trials evaluating the main reasons for treatment failure and whether this occurs during or after therapy. Other formats for combining effector cell with target specificity, and other targets such as CD33 and CD123 are currently under evaluation.
The above discussion is summarized in Table 1 , where we also speculate on ways to advance the field by combining the available therapeutic modalities.
Conclusions
We have entered a golden age of cellular immunotherapy. Rather than replacing other anticancer modalities such as surgery, chemotherapy, radiotherapy, or small molecule pathway inhibitors, it is likely that the bountiful harvest of new technology will be deployed in a complementary fashion to further individual and population-based outcomes from cancer.
Nonetheless, based on extant results, several conclusions can be drawn.
Of the modalities that do not require a priori knowledge of targets, checkpoint inhibitors have the unique ability to mediate convincing regressions of large volumes of disease in selected types of cancer with heavy mutational burden (or with exceptional levels of PDL1/PD1 interaction). The main side effects include high rates of autoimmune reactions, particularly when two different pathways are blocked simultaneously.
Numerical increase or non-specific activation of immune effector cells, such as transfer of NK cells, CIK cells, or infusion of cytokines with important roles in T cell homeostasis and development, leads to relatively minor responses in patients with cancer.
Antigen-specific T cells, redirected genetically or by means of bi-specific engaging peptides, have the most potent single agent activity in patients with advanced hematologic malignancies. Of these, CAR T cells appear the most active.
However, CAR T cells and bi-specific T cell engagers require a cell-surface target that is either unique to the tumor, or if not unique to the tumor then the normal cell counterpart that bears the targeted antigen must be at least temporarily dispensable (e.g., B cells).
T cells bearing a TCR specific for tumor-associated antigens (TAA) have the potential to mediate tumor-specific immunity. However, some TAA are at least in part shared by normal tissues. T cells that are specific for tumor-associated mutations have been generated from a handful of patients with solid tumors at great effort and expense and represent the purest example of tumor-specific adoptive cellular immunotherapy, but it remains to be seen whether the herculean efforts required to generate such T cell products can be generalized beyond single highly specialized centers.
Planes, trains, and automobiles each fulfil a unique nonredundant and complimentary role in a well-designed transportation system. Having a range of options facilitates customization and enables us to find the right solution to each given problem, be it how to get from geographical A to B, or how to fight cancer.
It is likely that in the coming years, we will learn which of the immunotherapeutic modalities is best suited for each role and where immunotherapy can be enhanced with or support more traditional methods of anticancer therapy. Given the relatively early stage of development of most of these modalities, 
